BRPI0520483A2 - método para detectar adenoma colorretal e/ou carcinoma colorretal, método para discriminar entre adenoma colorretal e carcinoma colorretal ou estados adicionais de tumor, método para monitorar desenvolvimento e/ou curso e/ou tratamento de adenoma colorretal e/ou carcinoma colorretal e/ou a discriminação entre diferentes estágios de tumor, uso de fragmento de endoplasmina, sistema de teste, arranjo, método para determinar se um composto é eficaz no tratamento de adenoma colorretal e/ou carcinoma colorretal e/ou estágios especìficos de tumor - Google Patents

método para detectar adenoma colorretal e/ou carcinoma colorretal, método para discriminar entre adenoma colorretal e carcinoma colorretal ou estados adicionais de tumor, método para monitorar desenvolvimento e/ou curso e/ou tratamento de adenoma colorretal e/ou carcinoma colorretal e/ou a discriminação entre diferentes estágios de tumor, uso de fragmento de endoplasmina, sistema de teste, arranjo, método para determinar se um composto é eficaz no tratamento de adenoma colorretal e/ou carcinoma colorretal e/ou estágios especìficos de tumor

Info

Publication number
BRPI0520483A2
BRPI0520483A2 BRPI0520483-6A BRPI0520483A BRPI0520483A2 BR PI0520483 A2 BRPI0520483 A2 BR PI0520483A2 BR PI0520483 A BRPI0520483 A BR PI0520483A BR PI0520483 A2 BRPI0520483 A2 BR PI0520483A2
Authority
BR
Brazil
Prior art keywords
colorectal
adenoma
colorectal carcinoma
carcinoma
tumor
Prior art date
Application number
BRPI0520483-6A
Other languages
English (en)
Inventor
Hartmut Juhl
Kerstin David
Anne-Kristin Fentz
Original Assignee
Indivumed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivumed Gmbh filed Critical Indivumed Gmbh
Publication of BRPI0520483A2 publication Critical patent/BRPI0520483A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

MéTODO PARA DETECTAR ADENOMA COLORRETAL E/OU CARCINOMA COLORRETAL, MéTODO PARA DISCRIMINAR ENTRE ADENOMA COLORRETAL E CARCINOMA COLORRETAL OU ESTADOS ADICIONAIS DE TUMOR, MéTODO PARA MONITORAR DESENVOLVIMENTO E/OU CURSO E/OU TRATAMENTO DE ADENOMA COLORRETAL E/OU CARCINOMA COLORRETAL E/OU A DISCRIMINAçãO ENTRE DIFERENTES ESTáGIOS DE TUMOR, USO DE FRAGMENTO DE ENDOPLASMINA, SISTEMA DE TESTE, ARRANJO, MéTODO PARA DETERMINAR SE UM COMPOSTO é EFICAZ NO TRATAMENTO DE ADENOMA COLORRETAL E/OU CARCINOMA COLORRETAL E/OU ESTáGIOS ESPECìFICOS DE TUMOR. A presente inven;ão é dirigida a um método para detectar adenoma colorretal e/ou carcinoma colorretal compreendendo as etapas de: a) fornecer um material de amostra isolado que foi tirado de um indivíduD, b) determinar o nível de um fragmento de endoplasmina ou um derivado do mesmo no material de amostra isolado, c) comparar o nível determinado de um fragmento de endoplasmina ou um derivado do mesmo com um ou mais valores de referência. A presente invenção é dirigida adicionalmente a um método para discriminar entre adenoma colorretal e carcinona colorretal bem como a um método para monitorar o desenvolvimento e/ou curso de adenoma colorretal e/ou carcinoma colorretal e/ou tratamento de adenoma colorretal e/ou carcinoma colorretal. Além disso, a presente invenção é dirigida a um sistema de teste e um arranjo para uso nesses métodos. Ajicionalmente, a invenção é dirigida ao uso de um fragmento de endoplasmina como biomarcador para detecção de adenoma c:olorretal e/ou carcinoma colorretal em um individuo. Além dThso, a presente invenção é dirigida a um método para determinar a eficácia de um composto no tratamento de adenoma colorretal e/ou carcinoma colorretal.
BRPI0520483-6A 2005-08-19 2005-08-19 método para detectar adenoma colorretal e/ou carcinoma colorretal, método para discriminar entre adenoma colorretal e carcinoma colorretal ou estados adicionais de tumor, método para monitorar desenvolvimento e/ou curso e/ou tratamento de adenoma colorretal e/ou carcinoma colorretal e/ou a discriminação entre diferentes estágios de tumor, uso de fragmento de endoplasmina, sistema de teste, arranjo, método para determinar se um composto é eficaz no tratamento de adenoma colorretal e/ou carcinoma colorretal e/ou estágios especìficos de tumor BRPI0520483A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/009005 WO2007019875A1 (en) 2005-08-19 2005-08-19 Use of an endoplasmin fragment and derivatives thereof as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system

Publications (1)

Publication Number Publication Date
BRPI0520483A2 true BRPI0520483A2 (pt) 2009-11-10

Family

ID=36087694

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520483-6A BRPI0520483A2 (pt) 2005-08-19 2005-08-19 método para detectar adenoma colorretal e/ou carcinoma colorretal, método para discriminar entre adenoma colorretal e carcinoma colorretal ou estados adicionais de tumor, método para monitorar desenvolvimento e/ou curso e/ou tratamento de adenoma colorretal e/ou carcinoma colorretal e/ou a discriminação entre diferentes estágios de tumor, uso de fragmento de endoplasmina, sistema de teste, arranjo, método para determinar se um composto é eficaz no tratamento de adenoma colorretal e/ou carcinoma colorretal e/ou estágios especìficos de tumor

Country Status (13)

Country Link
US (1) US8580489B2 (pt)
EP (1) EP1917530B1 (pt)
JP (1) JP4832519B2 (pt)
KR (1) KR101314959B1 (pt)
AT (1) ATE499612T1 (pt)
AU (1) AU2005335652A1 (pt)
BR (1) BRPI0520483A2 (pt)
CA (1) CA2617214C (pt)
DE (1) DE602005026587D1 (pt)
IL (1) IL189185A0 (pt)
MX (1) MX2008001818A (pt)
NO (1) NO20080510L (pt)
WO (1) WO2007019875A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2126579A2 (en) * 2007-02-27 2009-12-02 Sentoclone AB Multiplex detection of tumour cells using a panel of agents binding to extracellular markers
CN109584961A (zh) * 2018-12-03 2019-04-05 元码基因科技（北京）股份有限公司 基于二代测序技术检测血液微卫星不稳定的方法
CN110244047B (zh) * 2019-06-10 2023-11-03 广州市妇女儿童医疗中心 肺癌血清诊断标志物及其应用、肺癌相关可溶性蛋白的分离鉴定方法
KR102735773B1 (ko) * 2022-11-10 2024-11-27 을지대학교 산학협력단 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019967A1 (de) * 2000-04-20 2001-10-25 Fenning Biomed Gmbh Dr Antikörper gegen natives gp96, deren Herstellung und Verwendung
MXPA05006382A (es) 2002-12-20 2005-10-24 Hoffmann La Roche Uso de nicotinamida n-metiltransferasa como un marcador para cancer colorrectal.
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
US8580489B2 (en) 2013-11-12
EP1917530B1 (en) 2011-02-23
NO20080510L (no) 2008-05-19
ATE499612T1 (de) 2011-03-15
WO2007019875A1 (en) 2007-02-22
CA2617214A1 (en) 2007-02-22
EP1917530A1 (en) 2008-05-07
KR101314959B1 (ko) 2013-10-11
CA2617214C (en) 2013-02-12
AU2005335652A1 (en) 2007-02-22
US20100273668A1 (en) 2010-10-28
DE602005026587D1 (de) 2011-04-07
KR20080036652A (ko) 2008-04-28
MX2008001818A (es) 2008-04-09
JP2009505080A (ja) 2009-02-05
JP4832519B2 (ja) 2011-12-07
IL189185A0 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
Qi et al. Circulating long non-coding RNAs in cancer: current status and future perspectives
SI1776587T1 (sl) Uporaba C3a in njegovih derivatov kot biomarkerja za kolorektalni adenom in/ali karcinom; diagnostični postopki in testi, ki uporabljajo le-te
Jang et al. Expression of epithelial-mesenchymal transition–related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
ZA202000935B (en) Methods and materials for assessing and treating cancer
MX357550B (es) Microarn plasmaticos para la deteccion de cancer colorrectal temprano.
WO2018187496A3 (en) Plasma based protein profiling for early stage lung cancer prognosis
CY1118748T1 (el) Πολυπλεγμενοι προσδιορισμοι βασιζομενοι σε απταμερη
GB2427468A (en) Devices and methods for enrichment and alteration of circulating tumour cells and other particles
BR112018073178A2 (pt) método, matriz e uso dos mesmos
EA201370063A1 (ru) Фосфолипидом рака
Brentnall et al. Proteins that underlie neoplastic progression of ulcerative colitis
GB2494580A (en) Method for diagnosing lung cancer
Watanabe et al. The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery
WO2014161910A3 (en) Methods and arrays for use in biomarker detection for prostate cancer
IL189185A0 (en) Use of an endoplasmin fragment and derivatives thereof as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system
Perzanowska et al. An MRM‐Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung Cancer Pleural Effusions
WO2014044791A3 (en) Methods and kits for predicting the sensitivity of a subject to chemotherapy
BRPI0514314A (pt) método para detecção de e discriminação entre adenoma colorretal e/ou carcinoma colorretal, método para monitoramento de desenvolvimento e/ou curso e/ou de tratamento de adenoma colorretal e/ou carcinoma colorretal, uso de c3a ou derivado do mesmo, sistema de teste, conjunto compreendendo moléculas, método para determinar se um composto é efetivo no tratamento do adenoma colorretal e/ou carcinoma colorretal
WO2014134548A3 (en) Assay, methods and compositions for diagnosing cancer
MY206091A (en) Methods based on the detection of rad51 foci in tumor cells
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
Pang Effect of miR-21 on Oral Squamous Cell Carcinoma Cell Proliferation and Apoptosis Via Akt/PKB Signaling Pathway
GONG et al. Application of serum tumor markers for predicting chemotherapy efficacy and prognosis in advanced esophageal squamous cell carcinoma
RU2554657C1 (ru) Способ обнаружения рубинсодержащих кальцифиров

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO O PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE.